Ann: Presentation to highlight broader potential of Deoxymabs, page-86

Check out what can happen suddenly. Stock...ad this morning. And Osteopore (ASX:OSX) popped big on news of the start of first-in-human clinical trials for knee preservation in Singapore, where the medtech specialises in “3D-printed biomimetic and bioresorbable” implants. Its first patient was treated for knee preservation with Heparan Sulphate 3 (HS3) and aXOpore via a High Tibial Osteotomy (HTO) at the National University Hospital (NUH), Singapore.”

That's just for the start of the human trials (on knee preservation), without results.They've had a 12 month range from .032 to .755. They had a 500% intra day rise on the announcement, from intra day trading the previous day.